Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julian Adams

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
International Journal of Radiation Oncology, Biology, Physics|July 12, 2005
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinomaCarter Van Waes, Angela A Chang, Peter F Lebowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancerChristos N Papandreou, Danai D Daliani, Darrell Nix, et al.
The New England Journal of Medicine|June 27, 2003
A phase 2 study of bortezomib in relapsed, refractory myelomaPaul G Richardson, Bart Barlogie, James Berenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesRobert Z Orlowski, Thomas E Stinchcombe, Beverly S Mitchell, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 27, 2013
The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathwaySherri Smith, Jennifer Hoyt, Nigel Whitebread, et al.
Nature|November 10, 2016
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cellsOlivier De Henau, Matthew Rausch, David Winkler, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 9, 2006
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90Jens R Sydor, Emmanuel Normant, Christine S Pien, et al.
Journal of Medicinal Chemistry|October 10, 2008
Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonistsMartin R Tremblay, Marta Nevalainen, Somarajan J Nair, et al.
Blood|January 1, 2005
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesRobert Z Orlowski, Peter M Voorhees, Reynaldo A Garcia, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 23, 2018
Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancerGiorgia Zadra, Caroline F Ribeiro, Paolo Chetta, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
International Journal of Radiation Oncology, Biology, Physics|July 12, 2005
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinomaCarter Van Waes, Angela A Chang, Peter F Lebowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancerChristos N Papandreou, Danai D Daliani, Darrell Nix, et al.
The New England Journal of Medicine|June 27, 2003
A phase 2 study of bortezomib in relapsed, refractory myelomaPaul G Richardson, Bart Barlogie, James Berenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesRobert Z Orlowski, Thomas E Stinchcombe, Beverly S Mitchell, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 27, 2013
The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathwaySherri Smith, Jennifer Hoyt, Nigel Whitebread, et al.
Nature|November 10, 2016
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cellsOlivier De Henau, Matthew Rausch, David Winkler, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 9, 2006
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90Jens R Sydor, Emmanuel Normant, Christine S Pien, et al.
Journal of Medicinal Chemistry|October 10, 2008
Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonistsMartin R Tremblay, Marta Nevalainen, Somarajan J Nair, et al.
Blood|January 1, 2005
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesRobert Z Orlowski, Peter M Voorhees, Reynaldo A Garcia, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 23, 2018
Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancerGiorgia Zadra, Caroline F Ribeiro, Paolo Chetta, et al.
Pageof 7